Cancer Cell Therapy Market & Pipeline Insight
Since the past 3-5 years, a more complex therapeutic modality has been is emerging as cell therapies which have been developed to treat diseases which are not amenable to treatment with more classical pharmaceutical or biopharmaceutical products. This market offers the promise of successfully regenerating damaged tissues and organs in the body by replacing the damaged tissue and/or by stimulating the body’s own repair mechanisms to heal previously irreparable tissues. With their rising popularity, these therapies are becoming more cost effective and efficient.
The discovery of cell therapies has changed the notion that cancer was otherwise incurable. With the efficient capability of cell-based therapies, the number of patients being treated successfully of cancer and similar diseases has increased significantly in recent years, thus leading to the increasing popularity of cell therapy across the globe. Cell therapy for cancer treatment thus represents a paradigm shift in healthcare therapies and treatment by focusing on the basic reason of the occurrence of the disease by repairing, replacing or regenerating damaged cells of the body.
With the cell-based therapies growing significantly, it is expected that the future years would witness significant advancements in technology in the cell therapy market. Increasing incidence of cancer along with lack of adequate effective treatment is most likely to drive the cancer cell therapy technology in developed and developing nations. Among the emerging trends of the global market, the most prominent one is the development of sophisticated automation devices for cell expansion and culture process which could be used in the treatment of cancer and other life threatening diseases.
Additionally, cell based therapies, in the next 3-4 year horizon would be increasingly used to have a better and deeper understanding of the working of genetics in the early stages of cell development. This would in turn enable scientists to understand the reasons of abnormal development of cancer cells. Thus, with the complete knowledge of genetic basis for cell development, scientists would be in a better position to develop efficient drugs and prevent the spread of cancer.
“Cancer Cell Therapy Market & Pipeline Insight” Report Highlights & Findings:
- Cancer Cell Therapy Market Overview
- Cancer Cell Therapy Market Dynamics
- Clinical Pipeline by Phase, country & Target Indications
- Cancer Cell Therapy Drugs in Pipeline: 82
- Highest Number of Drugs in Preclinical Stage:29
- Suspended & Discontinued Drug Profiles
1.1 Origin of Cell Therapy
1.2 Composition of Cell Therapy
2. INTRODUCTION TO CANCER THERAPIES
2.1 Types of Stem Cell Transplants for Treating Cancer
2.2 Dendritic Cell Therapy
2.3 Targeted Cancer Therapies
3. CANCER CELL THERAPY MARKET OVERVIEW
3.1 Market Overview
3.2 Clinical Pipeline Insight
4. GLOBAL CANCER CELL THERAPY MARKET DYNAMICS
4.1 Market Drivers
4.2 Market Challenges
4.3 Future Outlook
5. CANCER CELL THERAPY DRUG CLINICAL TRIAL INSIGHT BY PHASE, COUNTRY & TARGET INDICATIONS
5.1 Unknown Phase
5.2 Research
5.3 Preclinical
5.4 Clinical
5.5 Phase I
5.6 Phase I/II
5.7 Phase II
5.8 Phase III
6. MARKETED CANCER CELL THERAPY CLINICAL INSIGHT & PATENT ANALYSIS
7. SUSPENDED & DISCONTINUED CANCER CELL THERAPY CLINICAL INSIGHT
7.1 No Development Reported
7.2 Discontinued
7.3 Suspended
8. COMPETITIVE LANDSCAPE
8.1 Adaptimmune
8.2 Apceth
8.3 Argos Therapeutics Inc
8.4 Celgene Cellular Therapeutics
8.5 Cellerant Therapeutics
8.6 Immunicum
8.7 Innate Pharma
8.8 Innocell Corporation
8.9 Kite Pharma
8.10 Takara Bio
LIST OF FIGURE
Figure 1-1: Four Pillars of Global Pharmaceutical Industry
Figure 1-2: Composition of Cell Therapy
Figure 2-1: Cancer Therapies Overview
Figure 3-1: Global Cell Therapy Market (US$ Billion), 2012-2018
Figure 3-2: Global Cell Therapy Market by Indications, 2013
Figure 3-3: Global Cell Therapy Market by Region (%), 2013 & 2018
Figure 3-4: Global Cancer Cell Therapy Market (US$ Billion), 2012-2018
Figure 3-5: Cancer Cell Therapy Clinical Pipeline by Phase (%), 2014
Figure 3-6: Cancer Cell Therapy Clinical Pipeline by Phase (Number), 2014
Figure 3-7: No Development Reported in Cancer Cell Therapy Clinical Pipeline by Phase (%), 2014
Figure 3-8: No Development Reported in Cancer Cell Therapy Clinical Pipeline by Phase (Number), 2014
Figure 3-9: Discontinued Cancer Cell Therapy Clinical Pipeline by Phase (%), 2014
Figure 3-10: Discontinued Cancer Cell Therapy Clinical Pipeline by Phase (Number), 2014
Figure 8-1: Adaptimmune Clinical Pipeline Insight
Figure 8-2: Apceth Clinical Pipeline Insight
Figure 8-3: Argos Therapeutics Clinical Pipeline Insight
Figure 8-4: Cellerant Clinical Pipeline Insight
Figure 8-5: Immunicum Clinical Pipeline Insight
Figure 8-6: Innate Pharma Clinical Pipeline Insight
Figure 8-7: Kite Pharma Clinical Pipeline Insight
Over the past 5 years, the global cell therapy market has witnessed huge investments in research and development activities, which have attracted the interests of many cell therapy industry firms, medical centers and academic institutions. Additionally, there have been many mergers, collaborations, acquisitions and partnerships taking place in the global cell therapy industry in the past x years, between the companies developing cell therapy technology. All these developments have led to the positive overall growth of the global cell therapy market. The global market for cell therapy was valued at close to USD xx Billion in 2012. With continuous advances and developments in this field of medicine, the global cell therapy market is expected to grow at a high rate of xx% to reach approximately USD xx Billion by 2018.
Several products and technologies of cell-based therapies are in the R&D pipeline which is expected to enter the market during the forecast period, thus resulting in an increased growth rate. Applications of cell-based therapies in Central Nervous System, bone and skin continue to expand. Other than these, cancer, neurology and diabetes are the other most popular indications for cell therapies. There are immense growth opportunities in these target therapeutic areas owing to the ever rising incidence of these life-threatening diseases in almost all countries of the world. There is a large unmet need for these diseases, which cell therapies can satisfy to a great extent.
Global Cell Therapy Market (US$ Billion), 2012-2018,_2012-2018.bmp)
The cell therapy market offers wide market potential and a favorable landscape for adoption across many geographical locations of the world. With a major part of the industry-sponsored clinical trials concentrated in the USA, this region accounts for the major share in the global pie followed by Europe and Asia-Pacific regions.
As the USA accounts for a dominant share of more than 50% in the global cell therapy market, there are more than xx cell therapy products commercially distributed by companies in the USA. These include Dermagraft, Osteocel, PureGen, BioDfactor, BioDfence, Provenge, Carticel, Epicel, Nucel, Appligraf, GINTUIT, Trinity, Grafix, DeNovoET, Prokera, and AmnioGraft. Though during the period 2001-09, no cell therapy products received regulatory approval, in the past few years, the market in USA has grown with 8 such approvals in quick succession.
In Europe, there are many stem cell sector products commercially distributed by companies in selected countries of the region like MySkin, CryoCell, ReCell, Carticel, Epicel, MACI, ChrondroCelect, AlloStem, BioSeed-C, co.don chondrospheres, Epidex, EpiGraft, and Diabecell. Additionally there are two point-of-care devices (by Therakos and Cytori) commercially marketed in Europe for cell-based treatments.
The global market for cancer cell therapy was valued at close to USD xx million in 2012. With the rising popularity of cell therapy in cancer treatment coupled with the growing incidence of this disease, the global cancer cell therapy market is expected to grow at a high CAGR of xxx% to reach approximately USD xxx billion by 2018. Several products and technologies for treating cancer based on cell-based therapies are in the R&D pipeline which is expected to enter the market during the forecast period. This, coupled with the rising demand of cancer patients, who are living longer, is expected to drive the future market.
